Abstract 123 Table 1

First author and yearGestational age and birth weight (Grams)Timing of INDO administrationSubject INDO w/NECControl group w/NECSubject INDO w/IPControl group w/IPNEC P-valueIP P-value
Grosfeld 1996 3 to 7 days of age 90/252 (35%) 105/764 (13.7%) 27/252 (10.7%) 13/764 (1.7%) p<0.02 p<0.05
Fujii 2002 ETG=Early Treatment: First 2 days of life ETG=10/30 (33%) STG=9/32 (28%) ETG=6/30 (20%) STG=0/32 (0%) p=0.659 p=0.011
STG=Standard Treatment: After 2 days of life
O’Donovan 2003 As needed for significant PDA 14/108 (13.0% I) 7/50 (14.0% L) 5/108 (4.6% I) 6/50 (12% L) NS NS
8/66 (12.0% I-L) 4/66 (6.1% I-L)
Dolberg 2005 24 to 34 weeks NR 109/1183 (9.2% PDA-I) 192/4488 (4.3% No PDA)
37/373 (9.9% PDA only)
NR NR Presence of PDA itself (not I) was significant for NEC NR
McPherson 2008 As needed for significant PDA 14/228 (6.1%) 47/628 (7.5%) 14/228 (6.1%) 4/628 (0.6%) NS p
Pumberger 2014 First 24 hours of life I+E+114/1186 (10%) I-E+239/3128 (8%) I+E+32/1186 (3%) I-E+35/3128 (1%) NS Unadjusted p
I+E- 461/4688 (10%) I-E- 667/6749 (8%) I+E- 177/4688 (4%) I-E- 207/6749 (3%)
Paquette 2006 First 48 hours of life 16 patients with IP 32 matched controls >2 doses of I plus>2 doses of ST increased risk of IP 9.6 times NS Increased risk of IP with I plus ST
  • NR=Not Reported, NS=Not Significant, I=Indomethacin Treatment, L=Surgical Ligation Treatment,E+=Late Feeding (during the first 3 days), E-=Late Feeding (>first 3 days), ST=Steroids